Wegovy vs Saxenda: Which GLP-1 Weight Loss Injection Works Better?

What Are Wegovy and Saxenda?

Both Wegovy and Saxenda belong to the GLP-1 receptor agonist class, meaning they mimic glucagon-like peptide-1 to slow gastric emptying, reduce appetite, and improve glucose regulation. The two drugs differ primarily in their active molecule, half-life, and dosing frequency. Wegovy uses semaglutide, a molecule with a 168-hour half-life that allows once-weekly subcutaneous injection. Saxenda uses liraglutide, which has a 13-hour half-life and therefore requires daily injection.

The FDA approved Saxenda in December 2014 for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. Wegovy received approval in June 2021 under the same BMI criteria. Both carry a black-box warning regarding thyroid C-cell tumors observed in rodent studies, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. [1][2]

Semaglutide's longer half-life is not a trivial chemical footnote. It translates directly into steadier plasma drug levels across the week, which some researchers believe contributes to stronger appetite suppression relative to liraglutide. [3]

Head-to-Head Trial: What STEP-8 Actually Found

The most direct comparison comes from STEP-8, a 68-week randomized controlled trial published in JAMA in 2022. Semaglutide 2.4 mg produced a mean weight loss of 15.8% of body weight versus 6.4% with liraglutide 3.0 mg (difference: 9.4 percentage points; P<0.001). [4]

Among participants who achieved at least 10% weight loss, 70.9% were in the semaglutide arm compared with 25.6% in the liraglutide arm. At the 15% threshold, 55.6% of semaglutide patients qualified versus only 12.0% of liraglutide patients.

Nausea and vomiting rates were similar between the two arms. Discontinuation due to adverse events occurred in 13.5% of semaglutide participants and 27.6% of liraglutide participants, suggesting that despite similar GI event rates, patients on daily liraglutide injections were more likely to stop treatment. The authors note that the frequency burden of daily versus weekly injections may partly explain this difference.

Those numbers matter clinically. A 15.8% mean weight loss approaches the threshold where patients often see meaningful reductions in blood pressure, HbA1c, and sleep apnea severity. A 6.4% loss, while clinically meaningful, less reliably crosses those thresholds. [4]

Semaglutide Long-Term Data: STEP-1 and STEP-5

STEP-8 is the head-to-head benchmark, but the broader STEP program adds important context about how semaglutide performs over time.

STEP-1 (N=1,961) randomized adults with obesity or overweight plus at least one comorbidity to semaglutide 2.4 mg or placebo for 68 weeks. The semaglutide group lost a mean 14.9% of body weight versus 2.4% in the placebo group (P<0.001). [3] Over one-third of semaglutide participants lost 20% or more of their baseline weight.

STEP-5 extended follow-up to 104 weeks in a cohort of 304 participants. Mean weight loss at two years was 15.2% with semaglutide versus 2.6% with placebo, showing that weight loss is maintained rather than attenuated with continued use. [5]

STEP-3 added intensive behavioral therapy on top of semaglutide in 611 participants, producing a mean weight loss of 16.0% at 68 weeks. [6] That figure suggests behavioral support amplifies the pharmacological effect, though the drug alone still drives the majority of the result.

How Saxenda Compares in Its Own Key Trial (SCALE)

Saxenda's primary registration trial, the SCALE Obesity and Prediabetes study, enrolled 3,731 adults with obesity or overweight. At 56 weeks, liraglutide 3.0 mg produced a mean weight loss of 8.4% of body weight versus 2.8% with placebo, with 63.2% of liraglutide patients achieving at least 5% weight loss. [7]

That trial enrolled a somewhat different population than STEP-1, so a direct percentage comparison requires caution. The cleanest comparison remains STEP-8. Still, Saxenda's absolute weight loss numbers in SCALE are substantially lower than semaglutide's in STEP-1, even accounting for methodological differences. A meta-analysis of GLP-1 receptor agonists published in The Lancet summarizes the dose-response relationship across agents, confirming semaglutide's superior efficacy within the class at approved weight-management doses. [8]

Where Tirzepatide (Zepbound) Fits Into This Picture

Readers comparing Wegovy and Saxenda often also ask how tirzepatide fits in. Tirzepatide, marketed as Zepbound for obesity and Mounjaro for type 2 diabetes, is a dual GIP/GLP-1 receptor agonist. It activates a second incretin pathway that semaglutide and liraglutide do not touch.

SURMOUNT-1 (N=2,539) tested tirzepatide 5 mg, 10 mg, and 15 mg against placebo in adults with obesity. At 72 weeks, mean weight loss was 15.0%, 19.5%, and 20.9% for the three doses respectively, compared with 3.1% for placebo. [9] The 15 mg dose produced weight loss roughly 5 percentage points greater than semaglutide's best trial performance. A head-to-head trial comparing tirzepatide directly to semaglutide at matched obesity-indication doses is ongoing as of early 2025, but published data do not yet exist.

SURMOUNT-4 demonstrated that patients who stopped tirzepatide after 36 weeks regained roughly two-thirds of their lost weight by week 88, reinforcing that these agents require continuous use to maintain results. [10]

Choosing Between Saxenda, Wegovy, and Zepbound: A Clinical Decision Framework

The table below organizes selection by patient profile. Clinicians at HealthRX use a three-axis approach: (1) required weight-loss magnitude, (2) injection frequency tolerance, and (3) insurance or cost constraints.

| Patient Profile | First-Line Choice | Rationale | |---|---|---| | Needs 10%+ weight loss, no T2D, weekly injection acceptable | Wegovy (semaglutide 2.4 mg) | STEP-8 superiority over liraglutide; once-weekly convenience | | Needs maximum weight loss, BMI >35, no cost barrier | Zepbound (tirzepatide 15 mg) | SURMOUNT-1 highest published efficacy in class | | Cannot tolerate weekly injections, prefers daily dosing | Saxenda (liraglutide 3.0 mg) | Daily titration; faster dose escalation if needed | | T2D present, weight loss secondary goal | Ozempic or Mounjaro per glycemic targets | Different FDA indications; discuss with prescriber | | Active cardiovascular disease, BMI >27 | Wegovy preferred | SELECT trial: 20% reduction in MACE at mean 34.2 months [11] |

Dosing Schedules: Wegovy vs Saxenda

The titration timelines differ markedly and affect tolerability in the first weeks of therapy.

Saxenda titration (5 weeks to maintenance)

• Week 1: 0.6 mg once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 onward: 3.0 mg once daily (maintenance)

Wegovy titration (16 weeks to maintenance)

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

Saxenda reaches its maintenance dose in 5 weeks; Wegovy takes 16 weeks. That slower escalation is deliberate. Semaglutide's longer half-life means plasma concentrations accumulate more gradually, and the extended titration reduces the intensity of nausea during dose increases. Patients who experience GI side effects at a given Wegovy dose can remain at that dose for an additional 4 weeks before escalating. [1]

The FDA label for Wegovy notes that if patients cannot tolerate the 2.4 mg maintenance dose, a temporary reduction to 1.7 mg is acceptable before re-attempting escalation. [1]

Side Effects: Comparing the Two Drugs

Both agents share a class-level GI side-effect profile. Nausea is the most frequently reported adverse event with either drug, typically most intense during the first few weeks after each dose increase.

Common to both (occurring in >5% of patients)

• Nausea (Wegovy: ~44%; Saxenda: ~40% in respective trials)
• Diarrhea
• Constipation
• Vomiting

Saxenda-specific considerations: Daily injections may cause more cumulative injection-site reactions than weekly dosing. The higher discontinuation rate in STEP-8 (27.6% vs 13.5% for semaglutide) may partly reflect injection fatigue. [4]

Wegovy-specific considerations: A small increase in resting heart rate (mean 1-4 bpm) is observed with semaglutide and appears class-related. Headaches are listed as a common adverse event in the Wegovy FDA label but not prominently in the Saxenda label. [1]

Serious risks shared by both drugs

• Pancreatitis (rare; discontinue if suspected)
• Gallbladder disease, including cholelithiasis
• Acute kidney injury (usually secondary to dehydration from GI events)
• Thyroid C-cell tumor risk (black-box warning; contraindicated in MEN2 or personal/family history of medullary thyroid carcinoma)

The American Association of Clinical Endocrinology (AACE) 2016 obesity guidelines state: "The benefits and risks of pharmacotherapy must be evaluated individually for each patient, with periodic reassessment." [12] That framing applies directly here. Neither drug is appropriate without a thorough history covering pancreatitis, gallbladder disease, and thyroid risk.

Cardiovascular Outcomes: A Critical Difference

Wegovy holds an advantage that Saxenda currently does not. The SELECT trial (N=17,604) tested semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity but without diabetes. At a mean follow-up of 34.2 months, semaglutide reduced major adverse cardiovascular events (MACE) by 20% compared with placebo (HR 0.80; 95% CI 0.72-0.90; P<0.001). [11]

The FDA updated the Wegovy label in March 2024 to include this cardiovascular risk reduction indication. Saxenda has no comparable outcome trial data in a cardiovascular-disease population, and its label carries no such indication. For patients with prior myocardial infarction, stroke, or peripheral arterial disease, that distinction may be clinically decisive.

Cost, Insurance Coverage, and Access

List prices for both drugs exceed $1,300 per month without insurance in the United States. Saxenda's list price sits around $1,400/month; Wegovy's around $1,350/month, though both change with manufacturer adjustments and pharmacy pricing. Neither figure reflects what insured patients pay out-of-pocket.

Manufacturer savings programs exist for both. Novo Nordisk's Wegovy savings card can reduce costs for commercially insured patients to as low as $0/month in some cases, though eligibility restrictions apply. A similar program exists for Saxenda.

Coverage by Medicare Part D for weight-loss indications remains limited under current law, though legislative proposals as of 2025 may change this. Medicaid coverage varies by state.

Because tirzepatide (Zepbound) is also manufactured by Eli Lilly and priced in a similar range, cost alone rarely distinguishes these three options clearly. The decision more often comes down to documented efficacy differences and individual tolerability.

Ozempic vs Wegovy: Why They Are Not the Same Drug

A frequent source of confusion: Ozempic and Wegovy both contain semaglutide, but they are distinct FDA-approved products with different indications and maximum doses.

Ozempic is approved for type 2 diabetes management and cardiovascular risk reduction in T2D patients, with a maximum approved dose of 2.0 mg weekly for glycemic control. Wegovy is approved for chronic weight management at 2.4 mg weekly. Using Ozempic off-label for weight loss at doses above 1.0 mg means prescribing outside the approved range for that specific product, even though the molecule is identical.

STEP-2, which enrolled 1,210 adults with T2D and obesity, tested semaglutide 2.4 mg versus 1.0 mg (the Ozempic dose most often used in diabetes) and found greater weight loss at 2.4 mg (9.6% vs 7.0% body weight at 68 weeks). [13] The incremental weight loss from the higher dose is meaningful.

Who Should Not Use Either Drug

Several absolute and relative contraindications apply across both agents. Per their respective FDA labels, neither Wegovy nor Saxenda should be used in patients with:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Pregnancy (both are Category X equivalent under current labeling)
• Known hypersensitivity to semaglutide or liraglutide or any excipient

Relative contraindications warranting careful discussion include a history of pancreatitis, significant gastroparesis, or inflammatory bowel disease, as slowed gastric motility can worsen these conditions.

Patients on sulfonylureas or insulin should also be counseled on hypoglycemia risk when adding any GLP-1 agent, as the combination can lower glucose more than either drug alone.

Practical Starting Points for HealthRX Patients

Starting either medication requires a few baseline steps: confirmation of BMI eligibility (30 or higher, or 27 or higher with comorbidity), screening for contraindications, and a documented discussion of realistic weight-loss expectations. Neither drug produces results in isolation. Both FDA labels specify use "as an adjunct to a reduced-calorie diet and increased physical activity." [1][2]

Patients who start Wegovy should expect the first 4 weeks to produce little weight change, since 0.25 mg is a sub-therapeutic dose used only for tolerability. Measurable appetite suppression typically begins at the 0.5 mg dose. Most patients reach maximum efficacy somewhere between weeks 36 and 68.

Saxenda patients may notice appetite reduction within the first two weeks given the faster titration, but peak weight loss in SCALE occurred around week 56.

If a patient achieves less than 4% weight loss after 16 weeks on a maintenance dose of either drug, the respective FDA labels advise discontinuing and reassessing the treatment plan.